DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50-Day Moving Average - Here's Why

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $21.20 and traded as high as $21.24. DBV Technologies shares last traded at $20.59, with a volume of 181,986 shares changing hands.Get DBV Technologies alerts:Analyst Ratings Changes3 Biopharmaceutical Stocks Bucking the Sell-OffDBVT has been the topic of several analyst reports. Citizens Jmp lifted their target price on DBV Technologies from $45.00 to $47.00 and gave the company a "market outperform" rating in a research note on Friday, March 27th. Wall Street Zen lowered shares of DBV Technologies from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a report on Wednesday, December 17th. Guggenheim reaffirmed a "buy" rating and issued a $51.00 price target on shares of DBV Technologies in a report on Friday, March 27th. Finally, Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $38.65.Read Our Latest Report on DBV TechnologiesDBV Technologies Price PerformanceThe company has a market capitalization of $1.15 billion, a PE ratio of -3.94 and a beta of -0.94. The stock's 50 day simple moving average is $21.20 and its 200-day simple moving average is $17.99. DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The business had revenue of $0.65 million for the quarter. On average, equities analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current year. Institutional Trading of DBV TechnologiesA number of large investors have recently modified their holdings of DBVT. Artisan Partners Limited Partnership increased its stake in DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company's stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the last quarter. Vivo Capital LLC grew its holdings in shares of DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company's stock worth $47,189,000 after buying an additional 1,407,120 shares during the last quarter. Siren L.L.C. purchased a new position in DBV Technologies in the 4th quarter valued at $35,606,000. Adage Capital Partners GP L.L.C. purchased a new position in DBV Technologies in the 2nd quarter valued at $9,659,000. Finally, MPM Bioimpact LLC purchased a new position in DBV Technologies in the 2nd quarter valued at $9,649,000. Hedge funds and other institutional investors own 71.74% of the company's stock. About DBV Technologies (Get Free Report)DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies. The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.Featured ArticlesFive stocks we like better than DBV TechnologiesThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in DBV Technologies Right Now?Before you consider DBV Technologies, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here